
How is AI changing pharma’s preclinical research activities?
Investing.com -- Artificial intelligence is reshaping pharmaceutical research by accelerating drug discovery and increasing demand for experimental data, potentially benefiting laboratory equipment suppliers, according to Bernstein.
In an October 16 report, Bernstein analysts highlighted findings from a webinar with Tom Fleming, co-founder and former CEO of automated laboratory services provider Arctoris.
Fleming said demand for AI training datasets has expanded beyond venture-backed biotechnology companies to major pharmaceutical groups, which now account for most of Arctoris’s data-generation business, excluding certain partnerships.
In some cases, demand for experimental data has increased tenfold or even 100-fold. However, declining costs per data point could offset the financial benefits of higher volumes.
Laboratory instruments capable of producing complex, high-value data at scale are expected to benefit most.
Fleming identified Revvity’s (NYSE) Opera Phenix high-content im












